Journal of Antimicrobial Chemotherapy

DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens

Erika van Eijk, Bert Wittekoek, Ed J. Kuijper and Wiep Klaas Smits*

Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

*Corresponding author. Tel: +31-71-526-1229; E-mail: w.k.smits@lumc.nl

With the impending crisis of antimicrobial resistance, there is an urgent need to develop novel antimicrobials to combat difficult infections and MDR pathogenic microorganisms. DNA replication is essential for cell viability and is therefore an attractive target for antimicrobials. Although several antimicrobials targeting DNA replication proteins have been developed to date, gyrase/topoisomerase inhibitors are the only class widely used in the clinic. Given the numerous essential proteins in the bacterial replisome that may serve as a potential target for inhibitors and the relative paucity of suitable compounds, it is evident that antimicrobials targeting the replisome are underdeveloped so far. In this review, we report on the diversity of antimicrobial compounds targeting DNA replication and highlight some of the challenges in developing new drugs that target this process.

Introduction

The increase in MDR bacteria has resulted in limited treatment options, and therefore the development of compounds directed against these microorganisms is of utmost importance. In recent years, the pipeline of new antimicrobials has almost dried up, apart from the approved follow-up compounds (second, third and fourth generations), which have the same mode of action as their predecessors.[1] The development of antimicrobials derived from existing scaffolds is not without risk, as these compounds may be vulnerable to the same resistance mechanisms. Therefore, exploring new potential targets and/or increasing structural diversity in the next-generation antimicrobials are paramount in minimizing the risk of rapid acquisition of antimicrobial resistance. There are several essential cellular processes that can serve as targets for novel antimicrobials and many of these are exploited by antimicrobials. Of particular interest for this review is DNA replication. Correct replication of DNA by a multi-protein complex, the replisome, and proteins associated with it (Table 1 and Figure 1) is an essential requirement for cell viability. The 'core' replisome complex consists of helicase, primase, DNA polymerase, sliding clamp, clamp loader and single-stranded DNA-binding (SSB) proteins. Stringent coordination of this complex is essential for DNA replication, and inhibition of the function of any of these proteins or their interactions in principle disrupts the process and results in cell death.[2] Other proteins that are crucial for DNA replication include topoisomerase II and DNA ligase.

Despite the potential of replication proteins to serve as a target for antimicrobial compounds, clinical use has primarily been limited to topoisomerase II inhibitors, which target DNA gyrase and/or topoisomerase IV (TopoIV). In this review we will discuss inhibitors that target 'core' replisome proteins as well as associated proteins that are crucial for DNA replication. We illustrate three key challenges (antimicrobial resistance, specificity and exploration of new targets) and potential strategies to meet these challenges using examples of novel DNA replication-targeting antimicrobials active against *Clostridium difficile* and other MDR pathogens.

Clinically used antimicrobials targeting DNA replication: topoisomerase II inhibitors

The two bacterial topoisomerase II enzymes – DNA gyrase and TopoIV – modify the topology of DNA during replication.[3] Gyrase and TopoIV are tetramers composed of two GyrA and two GyrB subunits (encoded by *gyrA* and *gyrB*) or two ParC and two ParE subunits (encoded by *parC* and *parE*), respectively.[4,5] Despite structural similarities,[3] the two topoisomerase II enzymes perform distinct functions in prokaryotes. Gyrase is able to introduce negative supercoiling into DNA, thereby relaxing the DNA helix, while TopoIV is specialized in DNA decatenation and unknotting of DNA.[6–8] Some bacteria only encode gyrase in their genome; it is possible that gyrase in these bacteria can efficiently decatenate DNA without TopoIV, as was shown with *Mycobacterium smegmatis*.[9]

Existing topoisomerase II inhibitors can roughly be divided into (i) ATPase inhibitors and (ii) topoisomerase II poisons that interfere with the catalytic DNA cleavage/joining process.[10] The first group is

Table 1. Diversity of targets in the bacterial DNA replication machinery

Function	E. coli	B. subtilis	C. difficile[a]	Activity	Inhibitors in (pre)clinical development
Chromosomal replication initiator protein	DnaA	DnaA	CD0001	initiation of DNA replication at oriC	
Replicative helicase	DnaB	DnaC	CD3657[b]	unwinding of double-stranded DNA at the replication fork	
Replicative helicase loader	DnaC	DnaI	CD3654[b]	required for functional loading of the replicative helicase	
Primosome protein	–	DnaB	–	replication initiation and membrane attachment; enhancing the helicase loading process, origin remodelling	
Primosome protein	–	DnaD	CD3653	initiation of DNA replication through interactions with other initiation proteins, origin remodelling	
Primase	DnaG	DnaG	CD1454[b]	synthesis of primers on the lagging strand	
Primosomal protein N′	PriA	PriA	CD2586		
Sliding clamp	β (DnaN)	DnaN	CD0002		griselimycins
Clamp loader complex	multiple proteins, including γ and τ (DnaX)	multiple proteins, including DnaX	multiple proteins, including CD0016		
DNA polymerase III α subunit DnaE	DnaE	DnaE	CD3396	elongation of leading and lagging strand during DNA synthesis (E. coli); initial extension of the RNA primers on the lagging strand (B. subtilis)	guanine inhibitors
DNA polymerase III α subunit PolC	–	PolC	CD1305	elongation of both leading and lagging strand during DNA synthesis	AUs, guanine inhibitors, non-nucleobase inhibitors
DNA polymerase I	PolA	PolA	CD1128	removal of RNA primers and gap filling	
Gyrase	GyrA, GyrB	GyrA, GyrB	CD0005, CD0006	relaxing the DNA double helix by introducing negative supercoils, catenating and decatenating DNA rings	FQs, NBTIs
Topoisomerase IV	ParE, ParC	ParE, ParC	–		FQs, NBTIs
DNA ligase	LigA	LigA	CD3309	joining of Okazaki fragments during DNA replication	ANCs, adenosine analogues
SSB protein	SSB protein	SSB protein	CD3662, CD3235	preventing degradation of single-stranded DNA in the replication fork; protein interaction platform	protein–protein interaction inhibitors

oriC, chromosomal origin of replication.
[a]Putative; most replication proteins of C. difficile are not characterized (apart from PolC).[91]
[b]These have been recently characterized.[104]

represented by the aminocoumarin class and the second group by the fluoroquinolones (FQs).

Aminocoumarins, such as the naturally occurring novobiocin, are cyclic peptides that compete with ATP to bind GyrB.[4,11]

Though novobiocin has little structural similarity with ATP, the binding sites of the drug partially overlap with the binding sites of ATP in GyrB.[12] Due to this overlap, mutations that confer aminocoumarin resistance are likely to affect the enzymatic activity of

Figure 1. Schematic representation of the variety of targets of antimicrobials in the bacterial replisome. Indicated is the core of the replisome and the other proteins that have been targeted by antimicrobial compounds. For simplicity, replication initiation proteins and regulators have been omitted from this figure. Important classes of drugs inhibiting specific proteins are boxed. The activity of all proteins is described in the main text. PPI, protein–protein interaction.

the topoisomerase.[10] Novobiocin was licensed for treatment of infections by staphylococci and other susceptible organisms, but the clinical use of aminocoumarins is very limited due to poor pharmacological properties (e.g. poor solubility, poor absorption). Though improvement of pharmacological properties may yield clinical candidates, none has entered trials yet.[13]

FQs are the most successful class of antimicrobials targeting DNA replication and among the most widely used antimicrobials on the market.[2] The FQ mode of action is to stabilize cleaved DNA–topoisomerase II complexes, thereby increasing the number of double-stranded DNA breaks in the bacterial cell.[14,15] Rapid cell death induced by FQs is likely the consequence of chromosome fragmentation, while inhibition of DNA replication results in reduced cell growth instead of cell death.[14] Most FQs are able to inhibit both gyrase and TopoIV with different efficiencies, with actual target preference depending on the specific compound and the bacterial species against which it is used.[14,16–18]

A major concern is the rise of FQ-resistant pathogens. FQs are commonly used to treat infections by Enterobacteriaceae, non-fermenting Gram-negative bacilli (in particular *Pseudomonas aeruginosa* and *Acinetobacter baumannii*) and *Mycobacterium tuberculosis*,[19,20] but resistance can also occur when FQs are used to treat infections with a different pathogen. For instance, increased use of FQs and simultaneous development of FQ resistance in clinical isolates of *C. difficile* resulted in the emergence of the epidemic PCR ribotype 027, as evidenced by whole-genome sequence data,[21,22] even though FQs are not the drug of choice to treat *C. difficile* infections. FQ resistance is mainly acquired through mutations in the so-called quinolone resistance-determining

regions (QRDRs) of the gyrase and/or TopoIV genes.[23] In most resistant pathogens the mutations are located in *gyrA* and/or *parC*, and rarely in *gyrB* or *parE*. In most Gram-positive bacteria, TopoIV is the primary target for FQs and resistance mutations arise first in *parC*. In contrast, mutations in most Gram-negative bacteria occur first in *gyrA*.[24] Single-step mutations can lead to resistance and the *C. difficile* example illustrates how such a single mutation can fuel an epidemic with detrimental clinical outcome. FQ resistance can also be conferred by non-specific efflux systems that can export quinolones and other antimicrobial agents or by plasmids harbouring a quinolone resistance determinant.[19]

Antimicrobials targeting DNA replication under development

There are many different compounds that have been identified as DNA replication inhibitors with potential to be used as an antimicrobial. These have been comprehensively reviewed elsewhere.[2,25] Here, we discuss several classes of DNA replication antimicrobials to highlight the diversity of replication proteins that can be exploited as targets and indicate some of the new developments.

Novel bacterial topoisomerase inhibitors (NBTIs)

Increasing FQ resistance has spurred the development of novel topoisomerase inhibitors that are active against FQ-resistant gyrase or TopoIV. Besides modifying existing FQ scaffolds,[26] novel non-quinolone topoisomerase II inhibitors, which are collectively

called NBTIs, have been developed.[13] Antimicrobials of this class target the catalytic core of topoisomerase, as do FQs, but NBTIs have a different mode of action. For example, the NBTI GKS299423 (GlaxoSmithKline) was shown to stabilize a pre-cleavage complex, in contrast to the cleavage complex with double-stranded DNA breaks targeted by FQs.[27] Examples of other NBTI compounds are a series of pyrazole derivatives and related tetrahydroindazoles,[28] NXL101,[29] NBTI 5463,[30] gyramides (N-benzyl-3-sulfonamidopyrrolidines),[31] and ACT-387042 and ACT-292706.[32] None of these compounds has entered clinical trials yet.

DNA ligase inhibitors

The primary function of bacterial NAD+-dependent DNA ligase (LigA) is to join the Okazaki fragments for the completion of lagging-strand DNA replication synthesis.[33] It is an attractive target for the development of novel antimicrobials as the ligase gene is present in all bacterial genomes and was found to be essential in several key pathogens.[33,34] It shares limited similarity to eukaryotic DNA ligase[34,35] and the binding of NAD+ as a substrate for ligase activity is a unique feature of bacterial ligase, limiting the potential for toxicity in humans.

All ligase inhibitors that have been developed to date are competitive inhibitors that bind a hydrophobic pocket near the binding site of the NAD+ substrate.[36] Four predominant classes of LigA inhibitors have been identified and here we will focus on the two most promising classes, the 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) and the adenosine analogues.[36]

The ANC scaffold was identified in high-throughput screening against *Escherichia coli* LigA (IC$_{50}$ of 25 μM), but displayed better activity against *Staphylococcus aureus* LigA (IC$_{50}$ of 2.5 μM).[37] The compound was not active against WT *E. coli* cells, however, due to poor permeability and efflux. Optimization of the ANC scaffold yielded compounds with improved activity (MIC 1–8 mg/L) against primarily Gram-positive pathogens (including MRSA and *C. difficile*), and promising results in animal models.[37]

Adenosine analogues were identified in high-throughput screening for inhibitors of *Haemophilus influenzae* LigA.[38,39] Biochemical experiments and X-ray crystallography showed that this class of compounds competes with NAD+ and blocks the AMP-binding pocket of the LigA adenylation domain. Adenosine analogues displayed good antimicrobial activities against both Gram-positive and Gram-negative bacteria *in vivo* (MIC 1–8 mg/L).[38] The initial adenosine analogues had favourable pharmacological properties (mainly good solubility) and one compound showed promise in *S. aureus* thigh infection and *Streptococcus pneumoniae* lung infection animal models.[38] However, the adenosine analogues were rapidly cleared in rats due to metabolism by cytochrome P-450s.[39,40] Despite attempts to optimize the solubility, antimicrobial activity and clearance of these compounds, there are no reports published on further progress.

Although the hydrophobic pocket near the binding site of the NAD+ substrate enables specific inhibition of the bacterial LigA by competitive inhibitors, it is not directly engaged in interactions with the NAD+ substrate.[33] A spontaneous resistant mutant of *S. aureus* contains a single leucine-to-phenylalanine mutation in the hydrophobic pocket that does not affect the ligase activity of the LigA mutant, but leads to a significant loss of target binding by

adenosine analogues.[33,38] This relatively high risk of resistance against this class of compounds may have contributed to the fact that no LigA inhibitors have been entered into human trials to date.

DNA polymerase III inhibitors

The bacterial DNA polymerase III α subunit (PolIII) is an essential enzyme for DNA replication as it is responsible for the synthesis of DNA and its potential as an antimicrobial target has been noted in recent *in silico* analyses of *E. coli* O157:H7 and *M. tuberculosis*.[41,42] Moreover, the distribution of two different homologues of the α subunit, PolC and DnaE, between Gram-positive and Gram-negative bacteria presents an opportunity to develop inhibitors specific to either group.[43] The first inhibitor of PolIII, 6-(p-hydroxyphenylazo)uracil (HPUra), was identified in 1970.[44] The majority of PolIII inhibitors specifically target PolC of low-G + C Gram-positive bacteria. Indeed, the single DnaE-specific compound reported to date (324C) did not demonstrate any *in vivo* antimicrobial activity against *Bacillus subtilis*, while it was highly active against purified *B. subtilis* DnaE *in vitro*.[45] The reason(s) for this is (are) unclear.

PolIII inhibitors can be categorized into three main classes: (i) the 6-anilinouracils (AUs); (ii) the guanine inhibitors; and (iii) the non-nucleobase inhibitors. The AU class of PolIII inhibitors, which includes HPUra, is composed of a uracil-containing base-pairing domain that binds the DNA at cytosine bases and an aryl domain that determines the selectivity and affinity for PolC.[46] AUs competitively inhibit PolC with respect to dGTP through simultaneous binding to the cytosine of the DNA strand and near the active site of PolC, resulting in a ternary inactive complex of AU inhibitor, DNA and PolC.[46,47] HPUra served as a scaffold for the development of numerous AUs with a broad range of antimicrobial and pharmacological properties. Two promising AUs, 6-(3-ethyl-4-methylanilino) uracil (EMAU) and 6-([3,4-trimethylene]anilino) uracil (TMAU), were highly active against PolC *in vitro*, but required optimization to increase activity against various Gram-positive bacteria, including MRSA.[46,48–50] Improvement of solubility of AUs compromises antimicrobial activity, but allowed the production of compounds that could be delivered intravenously rather than subcutaneously in animal models of infection.[46,50–52] The frequencies of mutations leading to AU resistance ranged from 3.6×10^{-10} to 1.2×10^{-8}, comparable to the frequency of ciprofloxacin resistance.[53] All mutations that conferred AU resistance were located at a specific amino acid in the presumed dNTP/AU-binding site of PolC.[53,54] Unexpectedly, however, the polymerase activity of these mutant PolC enzymes was unchanged in comparison with the WT *in vitro*.

The guanine inhibitors of bacterial DNA polymerase III have a purine moiety as the base-paring domain instead of the uracil ring of the AUs. They act via the same active site-directed competitive inhibition as AUs, but are active against both PolC and DnaE.[47,55,56] Two lines of guanine inhibitors have been developed: the N2-(3,4-dichlorobenzyl) guanines (DCBGs) and the N2-(3-ethyl-4-methylphenyl)guanines (EMPGs). N7-substituted DCBGs and EMPGs displayed potent *in vitro* antimicrobial activities against several Gram-positive pathogens, but showed limited efficacy in animal models.[47,56] Similar to the AUs, the DCBGs have poor solubility in water and no attempts have been made to produce soluble analogues so far.

The non-nucleobase class of DNA polymerase III inhibitors includes anilinopyrimidinediones (APs) and quinazolin-2-ylaminoquinazolin-4-ols (BisQuinols). The APs are structural isomers of AUs and are also competitive inhibitors of dGTP.[57] They show minimal cytotoxicity and moderate antimicrobial activities (MIC ranging from 8 to 16 mg/L).[57] In contrast to AUs and APs, BisQuinols have been suggested to compete with the DNA template, rather than nucleotides.[58] Though BisQuinol analogues were able to inhibit Gram-positive pathogens, they were unselective for mammalian Polδ, which raises concerns about cytotoxicity.

There is no information on resistance development against the guanine inhibitors or non-nucleobase inhibitors, but considering the similarities in mode of action to the AUs, caution is warranted.

Inhibitors of other replication-related proteins

The sliding clamp, or β subunit, of the replication machinery, is a polymerase processivity factor.[59,60] The protein can be targeted by novel griselimycins.[61] Griselimycin is a natural product of *Streptomyces griseus* with specific activity against the Corynebacterineae suborder, including *Mycobacterium* species.[62] The development of this class of compounds as anti-tuberculosis drugs was initially abandoned as rifampicin became available for treatment, but was revisited in light of its activity against drug-resistant isolates.[63] Poor pharmacokinetic properties of griselimycin were addressed by the total synthesis of derivatives.[61] In particular, cyclohexylgriselimycin was highly active against *M. tuberculosis in vitro* and in a mouse model of infection, comparable to isoniazid. Evidence for the mechanism of action came from observations that the griselimycin biosynthetic operon contains a sliding clamp homologue capable of conferring resistance to a susceptible *Streptomyces* strain, the selective amplification of a *dnaN*-containing chromosomal fragment in mycobacterial strains with evolved resistance (i.e. resistant strains harbouring multiple copies of the *dnaN* gene), and the crystal structure of griselimycin in complex with DnaN.[61]

Single-stranded DNA at the replication fork is stabilized and protected by SSB proteins.[64] These proteins are also an integral part of nucleoprotein complexes involved in recombination and repair.[65,66] Although present in all domains of life, the amino acid sequence, subunit composition and oligomeric state of these proteins differ substantially between organisms.[65] The essential role of SSB protein–protein interactions and low sequence similarity between eukaryotic and prokaryotic SSB proteins allows the potential development of SSB protein–protein interaction inhibitors that could serve as novel antimicrobials.[66] Indeed, small molecules that interfere with the interaction between SSB proteins and one or several binding partners have been identified by a high-throughput fluorescence polarization assay.[66,67] Inhibition by these compounds is based on mimicking the SSB protein C-terminus, which acts as a platform for interaction with other proteins, or more targeted inhibition of the SSB protein/exonuclease I (binding partner) interface.[66]

Challenges in developing novel antimicrobials targeting replication

We consider three main challenges in the development of novel antimicrobial compounds. First, novel antimicrobials should overcome resistance to known drugs and minimize development of resistance against the new drug. Second, they should preferably be specific to the microorganism/pathogen of interest to prevent dysbiosis of the host microbiome. The third challenge is to move away from modification and optimization of existing scaffolds that inhibit established cellular targets and explore novel targets and mechanisms of action. In the following section, we illustrate these challenges with a focus on compounds inhibiting the MDR organism *C. difficile*.

Challenge: antimicrobial resistance

The use of any antimicrobial agent exerts a selective pressure on susceptible bacterial populations, thereby creating an environment where the development of antimicrobial resistance is selected for. It can be assumed that resistance to any antimicrobial is unavoidable. Though resistance is reported to nearly all of the discussed replication antimicrobials, the likelihood of developing resistance varies greatly between classes. For example, mutations that confer resistance to LigA inhibitors do not affect the activity of the enzyme, while most mutations leading to aminocoumarin resistance impair gyrase functioning. Both antimicrobials target the active site of their target enzymes, but the binding sites of LigA inhibitors are located in a region that is not directly involved in substrate (NAD+) binding of LigA. Antimicrobials targeting DNA replication proteins that bind their targets at the active site, such as the aminocoumarins, have a relatively low risk of resistance, since mutations that affect drug–protein binding tend to lead to a non-functional protein.

LigA inhibitors, PolC inhibitors and most aminocoumarins target one specific protein and therefore a single mutation is frequently sufficient to cause resistance. FQs are able to target both gyrase and TopoIV. As a result, a high level of FQ resistance usually requires the presence of mutations in both gyrase and TopoIV,[68] which reduces the risk of resistance development. However, variations in the potency of FQs against gyrase and TopoIV still enable the emergence of resistant bacteria,[14] and for organisms that only have gyrase encoded in their genome, such as *C. difficile*, a single mutation is still sufficient to cause resistance. Indeed, a single mutation in *gyrA* (Thr82Ile) was most frequently found in FQ-resistant clinical *C. difficile* isolates.[69]

Two promising strategies that might reduce development of resistance (and cross-resistance) are (i) to target multiple proteins in the bacterial cell, using so-called hybrid antimicrobials, or (ii) to use multiple binding sites in a single target. Multi-targeting reduces the chance of resistance development and results in compounds that remain active against mutants resistant to either one of the parent compounds. Though polypharmacological modelling and rational design of multi-targeting drugs is a major challenge,[70,71] interesting progress has been made in recent years.

In FQ hybrid antimicrobials, a FQ moiety is covalently linked to another pharmacophore, with a distinct cellular target.[72] Various FQ hybrid classes have been developed, but of particular interest here are the AU–FQ hybrids, since both moieties target DNA replication. The AU–FQ hybrid class was created by linking various FQs to the N3 of the PolIIIC inhibitor HB-EMAU, with different linkers to modulate antimicrobial activity and pharmacological properties.[73] AU–FQ hybrids are highly active against Gram-positive

bacteria, and some compounds had moderate activity against the Gram-negative *E. coli*. MBX-500, one of the best AU–FQ hybrids, displayed 3-fold stronger inhibition of *B. subtilis* PolC than the AU moiety alone, while it showed 5- to 10-fold less potent inhibition of *B. subtilis* TopoIV and gyrase in comparison with the FQ component.[74] Despite these differences in target inhibition, MBX-500 had strong antimicrobial activities against *Bacillus* species (MIC of 0.156 mg/L), *S. aureus* strains (MIC ranging from 0.625 to 5 mg/L) and various other Gram-positive bacteria. As expected, MBX-500 retained high antimicrobial activity against strains that were resistant to the FQ component. Resistance to MBX-500 was only found in an AU- and FQ-resistant *S. aureus* that carried mutations in both targets, thereby providing evidence that MBX-500 truly acts via a dual-targeting mechanism. Indeed, the spontaneous mutation frequency against MBX-500 was low ($<5.6 \times 10^{-10}$ at $4 \times$ MIC); no resistant *S. aureus* strains could be isolated after a single passage, whereas *S. aureus* did develop resistance against the individual AU and FQ components.[74] The antimicrobial properties of MBX-500 were also investigated in *C. difficile*,[75] where FQ resistance is widespread among clinical strains.[69] The compound was active against a panel of 30 *C. difficile* isolates (MIC range 1–4 mg/L), which included several multiresistant strains and isolates from the epidemic PCR ribotype 027. Thus, dual-target antimicrobials are promising for the fight against resistant pathogens, and the low mutation frequencies (e.g. no spontaneous resistance) indicate a possible reduced risk of resistance development in comparison with single-target compounds.

Another approach to avoiding cross-resistance and reducing the risk of resistance is to identify multiple (novel) binding sites or multiple modes of action in a single established target, as exemplified by the novel topoisomerase II inhibitor kibdelomycin.[76] Biochemical studies in *S. aureus* showed that kibdelomycin is a potent ATPase inhibitor of both topoisomerase II enzymes, although it is >80-fold more active against the ATPase subunit of gyrase than TopoIV. The co-crystal structures of kibdelomycin bound to the N-terminal domains of *S. aureus* GyrB and ParE revealed a novel mode of 'dual' ATPase inhibition by blocking ATP binding and destabilizing GyrB/ParE subunit dimerization.[77] Kibdelomycin displays strong antimicrobial activities against predominantly Gram-positive bacteria, including MRSA and *C. difficile*.[78,79] The MIC$_{90}$ for *C. difficile* was 0.5 mg/L, similar to the novel therapeutic fidaxomicin, but more potent than metronidazole and vancomycin.[78] Importantly, kibdelomycin was equally active against FQ-resistant and -susceptible strains and showed favourable pharmacokinetics in mice and promise in a hamster model of *C. difficile* infection.[78] Kibdelomycin also retained antimicrobial activity against *S. aureus* strains resistant to novobiocin and coumermycin A1, two known ATP inhibitors of topoisomerase II, and showed a low frequency of resistance development ($<5.4 \times 10^{-10}$).[76] The MIC of kibdelomycin for a coumermycin-resistant *S. aureus* strain carrying three mutations in GyrB was modestly increased from 1 to 4 mg/L relative to the susceptible WT strain. This was attributed to one of the three mutations (Ile175Thr) in GyrB, which also interfered with kibdelomycin binding. Although the reduced susceptibility of the coumermycin A1-resistant strain warrants some caution, the data suggest that complete resistance caused by a single point mutation is not likely to occur due to the dual binding mode of this compound.

Challenge: specificity of novel antimicrobials

The normal gut microbiota is a diverse community of microbes that lives in a complex ecological system with its host.[80] With the increasing knowledge on interactions and dynamics of the microbiota with its host, it becomes evident that the human microbiome is of great importance for the prevention and treatment of infectious diseases. It can act as a protective barrier that prevents colonization of the gut by non-commensal pathogens and opportunistic pathogens that are already present. This so called colonization resistance[81] is greatly influenced by the diversity of the gut microbiota. Many broad-spectrum antimicrobials used in the clinic are known to affect the composition of the gut microbiota.[82,83] Colonization of the gut by pathogenic *C. difficile* is believed to require the disruption of the gut microbiota,[84,85] and patients with recurrent *C. difficile* infection (CDI) have a reduced diversity of their microbiota compared with healthy controls and patients with initial CDI.[86] There is a strong association between the use of broad-spectrum antimicrobials and increased risk of (recurrent) disease.[87,88] Patients treated with the narrow-spectrum antimicrobial fidaxomicin had lower *C. difficile* recurrence rates in comparison with broad-spectrum vancomycin,[89] which was attributed to the minimal impact of fidaxomicin on the gut microbiota, especially on bacteria of the *Bacteroides* cluster, clostridial cluster XIVa and bifidobacteria.[89,90] The example of *C. difficile* underscores that it is desirable for novel antimicrobials to limit the impact on the human microbiota as a whole.

Two strategies to generate or identify compounds with a narrow spectrum are (i) to test derivatives of an existing inhibitor for increased specificity and (ii) to screen for compounds with selective inhibition of a specific pathogen.

The first strategy has been used to identify and develop PolC inhibitors with increased species specificity. Many PolC inhibitors have a broad Gram-positive spectrum and are therefore likely to significantly affect the composition of the microbiota. However, the isolation and purification of the *C. difficile* PolC as well as polymerases from various other organisms enabled the identification of a series of novel 7-substituted DCBG inhibitors that showed improved potency and specificity against *C. difficile*.[91] One of these compounds, 362E, showed potent antimicrobial activity against *C. difficile* strains, similar to the first-line therapeutics metronidazole and vancomycin (MIC$_{90}$ of 4 mg/L).[91,92] Limited *in vitro* tests indicated that 362E is inactive against certain other Gram-positive anaerobes,[91] but the impact of 362E on the gut microbiota has not been reported to date. 362E protected hamsters from death due to *C. difficile* similarly to vancomycin and, though recurrent CDI was observed in both treatment groups when animals were treated for 3 days, prolonged treatment with 362E resulted in a reduced recurrence rate.[92] Further experimental evidence is needed to confirm the selectivity of this compound for *C. difficile* during *in vivo* treatment.

A second approach is to screen compounds *de novo* for specific activity against certain pathogens and couple this to an assay to determine the desired mode of action. SMT19969 (ridinilazole) is a bis(4-pyridyl)bibenzimidazole that has been specifically developed as a novel front-line antimicrobial for CDI treatment (MIC 0.06–0.5 mg/L)[93,94] with a low chance of resistance development.[95] Although the mode of action awaits validation, compounds of the

bisbenzimidazole class were shown to bind the minor groove of the DNA duplex and are thought to inhibit DNA replication through inhibition of DNA helicases and/or topoisomerases.[96] SMT19969 showed high selectivity for *C. difficile* relative to other intestinal isolates during *in vitro* susceptibility testing. In a Phase I clinical trial, treatment with SMT19969 resulted in minimal changes in the composition of the faecal microbiota of healthy human subjects, except for a significant reduction in total clostridial count,[97] and this was confirmed in an *in vitro* gut model of CDI.[98] SMT19969 was superior to vancomycin and, in a subset of strains, to fidaxomicin in a hamster model of recurrent CDI.[94,97] A clinical Phase II trial is currently ongoing where the efficacy of SMT19969 treatment will be compared with that of vancomycin treatment in CDI patients. In another example, as discussed above, kibdelomycin showed potent antimicrobial activities against a large panel of *C. difficile* isolates.[78] In contrast to metronidazole, kibdelomycin is mostly inactive against Gram-negative anaerobes, including the *Bacteroides fragilis* group, similar to the narrow-spectrum drug fidaxomicin.[78] The narrow spectrum of fidaxomicin is believed to contribute to its favourable characteristics in treating recurrent CDI,[89] but the effect of kibdelomycin on recurrent disease has not been investigated yet. MBX-500 also had little activity against most Gram-negative anaerobes, and was selectively active against *C. difficile* strains among Gram-positive anaerobes.[75] MBX-500 was shown to be efficacious in a gnotobiotic piglet model of acute CDI, with a 100% survival rate and only mild CDI symptoms.[99] Though the efficacy of MBX-500 was comparable to that of vancomycin in a hamster model of CDI, it was superior in a murine model of recurrent CDI and associated with improved weight gain in both animal models.[75] The weight gain of infected animals treated with MBX-500 and the results in the murine model suggest that this compound might have a low impact on the gut microbiota.

Narrow-spectrum antimicrobials are useful to prevent or treat opportunistic infections, such as CDI, that are associated with dysbiosis of the microbiome. Careful assessment of the effects on microbiota should be considered for all antimicrobials developed in the future.

Challenge: identifying novel targets in the bacterial replisome

Despite the success of the FQs, the number of compounds targeting DNA replication in clinical use or development is relatively low compared with inhibitors of other cellular processes, such as protein synthesis. Why is this group of antimicrobials underdeveloped, considering that there are many more proteins in the bacterial replisome?

A major issue is the poor characterization of the DNA replication machinery of important pathogens. For instance, the DNA replication proteins in *C. difficile* are merely predicted through homology with proteins in other organisms (Table 1), but functional evidence is limited to *C. difficile* PolC so far.[91] It can be expected that the extensive biochemical and structural characterization of replisome proteins of drug-resistant pathogens might lead to the identification of unique features that can be used to design antimicrobials that specifically target this specific species.

Another possible explanation for the underdevelopment of antimicrobials targeting DNA replication is that screens for replication inhibitors have been notoriously difficult. Most inhibitors are evaluated through *in vitro* biochemical assays that measure inhibition of either enzymatic activity or DNA replication and these are not always suitable for high-throughput screening.[25] Moreover, compounds identified this way may display potent *in vitro* activity, while they have no activity against bacterial cells *in vivo* due to undesirable pharmacokinetic properties. Besides some of the examples mentioned (aminocoumarins, ANCs and PolIII inhibitors), this is illustrated by two studies on inhibitors of the bacterial primosome.[100,101] Inhibitor peptides that target the DnaB–DnaG helicase–primase complex in *Bacillus stearothermophilus* were able to inhibit purified proteins *in vitro*,[100] but were inactive *in vivo*. A highly active triaminotriazine inhibitor of the *P. aeruginosa* replicative helicase DnaB did not show antimicrobial activity towards WT *P. aeruginosa* or *E. coli*, showed poor activity against *S. aureus* and showed problematic toxicity towards mammalian cells.[101] To circumvent the limitations of biochemical assays, screening could be performed using a whole-cell assay. By limiting the levels of a certain replisome protein or affecting its function in cells,[102,103] screens can be enriched for compounds that target DNA replication. A successful application of a whole-cell screen is the identification of vibrepin as an inhibitor of DNA replication in *Vibrio*.[103] *Vibrio* species, including the causative agent of cholera (*Vibrio cholerae*) have a bipartite genome, where replication of the second chromosome is dependent on the replication initiator RctB. In the screen, the growth of an *E. coli* strain harbouring an RctB-dependent plasmid with an antimicrobial resistance determinant was evaluated in the presence and absence of the antimicrobial and inhibition of growth was indicative of an RctB inhibitor. Vibrepin was found to interfere with chromosome II origin opening by RctB *in vitro* and inhibited various *Vibrio* species (MIC 0.4–2.0 mg/L), but also inhibited various other species via an RctB-independent mechanism.[103] This example also illustrates how differences between replication machineries can be exploited to work towards species-specific antimicrobial compounds.

Outlook

Despite the challenges that are discussed with respect to antimicrobials targeting DNA replication, we feel it is important to focus research on the identification of novel therapeutic targets in the bacterial replication machinery, whether they are individual proteins or protein–protein interactions,[25] for several reasons. First, DNA replication is essential for cell viability and inhibiting any essential protein would be detrimental for cell survival. Second, most components of the bacterial replisome are substantially different from their eukaryote counterparts and can therefore be exploited to develop compounds with minimal cytotoxicity. Third, antimicrobials directed at novel targets are likely to avoid existing resistance mechanisms. And finally, some components are well conserved between most bacteria, such as the DNA initiator protein DnaA, while others are more restricted to certain species Therefore, the bacterial replisome can be used to develop both broad- and narrow-spectrum antimicrobials. Recent insights on the structure of several DNA replication proteins and their inhibitors and the development of new assays that enable high-throughput screening for inhibitors of

DNA replication are expected to influence the rate of success of this class of antimicrobials considerably.[2]

Transparency declarations
E. V. E. and W. K. S. have performed research for Cubist. E. J. K. has performed research for Cubist, Novartis and Qiagen, and has participated in advisory forums of Astellas, Optimer, Actelion, Pfizer, Sanofi Pasteur and Seres Therapeutics. The companies, and the funding agencies above, had no role writing this manuscript. B. W.: none to declare.

References
1 Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. *J Antibiot (Tokyo)* 2014; **67**: 7–22.

2 Sanyal G, Doig P. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. *Expert Opin Drug Discov* 2012; **7**: 327–39.

3 Sissi C, Palumbo M. In front of and behind the replication fork: bacterial type IIA topoisomerases. *Cell Mol Life Sci* 2010; **67**: 2001–24.

4 Mizuuchi K, Mizuuchi M, O'Dea MH *et al*. Cloning and simplified purification of *Escherichia coli* DNA gyrase A and B proteins. *J Biol Chem* 1984; **259**: 9199–201.

5 Kato J, Nishimura Y, Imamura R *et al*. New topoisomerase essential for chromosome segregation in *E. coli*. *Cell* 1990; **63**: 393–404.

6 Gellert M, Mizuuchi K, O'Dea MH *et al*. DNA gyrase: an enzyme that introduces superhelical turns into DNA. *Proc Natl Acad Sci USA* 1976; **73**: 3872–6.

7 Deibler RW, Rahmati S, Zechiedrich EL. Topoisomerase IV, alone, unknots DNA in *E. coli*. *Genes Dev* 2001; **15**: 748–61.

8 Zechiedrich EL, Khodursky AB, Cozzarelli NR. Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in *Escherichia coli*. *Genes Dev* 1997; **11**: 2580–92.

9 Manjunatha UH, Dalal M, Chatterji M *et al*. Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase. *Nucleic Acids Res* 2002; **30**: 2144–53.

10 Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. *Appl Microbiol Biotechnol* 2011; **92**: 479–97.

11 Sugino A, Higgins NP, Brown PO *et al*. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. *Proc Natl Acad Sci USA* 1978; **75**: 4838–42.

12 Lewis RJ, Singh OM, Smith CV *et al*. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. *EMBO J* 1996; **15**: 1412–20.

13 Ehmann DE, Lahiri SD. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. *Curr Opin Pharmacol* 2014; **18**: 76–83.

14 Drlica K, Hiasa H, Kerns R *et al*. Quinolones: action and resistance updated. *Curr Top Med Chem* 2009; **9**: 981–98.

15 Wohlkonig A, Chan PF, Fosberry AP *et al*. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. *Nat Struct Mol Biol* 2010; **17**: 1152–3.

16 Pan XS, Fisher LM. Targeting of DNA gyrase in *Streptococcus pneumoniae* by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. *Antimicrob Agents Chemother* 1997; **41**: 471–4.

17 Fournier B, Zhao X, Lu T *et al*. Selective targeting of topoisomerase IV and DNA gyrase in *Staphylococcus aureus*: different patterns of quinolone-induced inhibition of DNA synthesis. *Antimicrob Agents Chemother* 2000; **44**: 2160–5.

18 Takei M, Fukuda H, Kishii R *et al*. Target preference of 15 quinolones against *Staphylococcus aureus*, based on antibacterial activities and target inhibition. *Antimicrob Agents Chemother* 2001; **45**: 3544–7.

19 Redgrave LS, Sutton SB, Webber MA *et al*. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. *Trends Microbiol* 2014; **22**: 438–45.

20 Zumla AI, Gillespie SH, Hoelscher M *et al*. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. *Lancet Infect Dis* 2014; **14**: 327–40.

21 McDonald LC, Killgore GE, Thompson A *et al*. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* 2005; **353**: 2433–41.

22 He M, Miyajima F, Roberts P *et al*. Emergence and global spread of epidemic healthcare-associated *Clostridium difficile*. *Nat Genet* 2013; **45**: 109–13.

23 Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. *Biochemistry* 2014; **53**: 1565–74.

24 Jacoby GA. Mechanisms of resistance to quinolones. *Clin Infect Dis* 2005; **41** Suppl 2: S120–6.

25 Robinson A, Causer RJ, Dixon NE. Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. *Curr Drug Targets* 2012; **13**: 352–72.

26 Wiles JA, Bradbury BJ, Pucci MJ. New quinolone antibiotics: a survey of the literature from 2005 to 2010. *Expert Opin Ther Pat* 2010; **20**: 1295–319.

27 Bax BD, Chan PF, Eggleston DS *et al*. Type IIA topoisomerase inhibition by a new class of antibacterial agents. *Nature* 2010; **466**: 935–40.

28 Gomez L, Hack MD, Wu J *et al*. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis. *Bioorg Med Chem Lett* 2007; **17**: 2723–7.

29 Black MT, Stachyra T, Platel D *et al*. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. *Antimicrob Agents Chemother* 2008; **52**: 3339–49.

30 Dougherty TJ, Nayar A, Newman JV *et al*. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. *Antimicrob Agents Chemother* 2014; **58**: 2657–64.

31 Foss MH, Hurley KA, Sorto N *et al*. N-benzyl-3-sulfonamidopyrrolidines are a new class of bacterial DNA gyrase inhibitors. *ACS Med Chem Lett* 2011; **2**: 289–92.

32 Lepak AJ, Seiler P, Surivet JP *et al*. In vivo pharmacodynamic target investigation of two bacterial topoisomerase inhibitors, ACT-387042 and ACT-292706, in the neutropenic murine thigh model against *Streptococcus pneumoniae* and *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2016; **60**: 3626–32.

33 Jahic H, Liu CF, Thresher J *et al*. The kinetic mechanism of *S. pneumoniae* DNA ligase and inhibition by adenosine-based antibacterial compounds. *Biochem Pharmacol* 2012; **84**: 654–60.

34 Shuman S. DNA ligases: progress and prospects. *J Biol Chem* 2009; **284**: 17365–9.

35 Korycka-Machala M, Rychta E, Brzostek A *et al*. Evaluation of NAD(+)-dependent DNA ligase of mycobacteria as a potential target for antibiotics. *Antimicrob Agents Chemother* 2007; **51**: 2888–97.

36 Swift RV, Amaro RE. Discovery and design of DNA and RNA ligase inhibitors in infectious microorganisms. *Expert Opin Drug Discov* 2009; **4**: 1281–94.

37 Surivet JP, Lange R, Hubschwerlen C *et al*. Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity. *Bioorg Med Chem Lett* 2012; **22**: 6705–11.

38 Mills SD, Eakin AE, Buurman ET *et al*. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo. *Antimicrob Agents Chemother* 2011; **55**: 1088–96.

39 Stokes SS, Huynh H, Gowravaram M *et al*. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity. *Bioorg Med Chem Lett* 2011; **21**: 4556–60.

40 Stokes SS, Gowravaram M, Huynh H *et al*. Discovery of bacterial NAD(+)-dependent DNA ligase inhibitors: improvements in clearance of adenosine series. *Bioorg Med Chem Lett* 2012; **22**: 85–9.

41 Mondal SI, Ferdous S, Jewel NA *et al*. Identification of potential drug targets by subtractive genome analysis of *Escherichia coli* O157:H7: an in silico approach. *Adv Appl Bioinform Chem* 2015; **8**: 49–63.

42 Jadaun A, Sudhakar DR, Subbarao N *et al*. In silico screening for novel inhibitors of DNA polymerase III alpha subunit of *Mycobacterium tuberculosis* (MtbDnaE2, H37Rv). *PLoS One* 2015; **10**: e0119760.

43 Timinskas K, Balvociute M, Timinskas A *et al*. Comprehensive analysis of DNA polymerase III alpha subunits and their homologs in bacterial genomes. *Nucleic Acids Res* 2014; **42**: 1393–413.

44 Brown NC. 6-(p-Hydroxyphenylazo)-uracil: a selective inhibitor of host DNA replication in phage-infected *Bacillus subtilis*. *Proc Natl Acad Sci USA* 1970; **67**: 1454–61.

45 Barnes MH, Butler MM, Wright GE *et al*. Antimicrobials targeted to the replication-specific DNA polymerases of gram-positive bacteria: target potential of dnaE. *Infect Disord Drug Targets* 2012; **12**: 327–31.

46 Tarantino PM Jr, Zhi C, Wright GE *et al*. Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria. *Antimicrob Agents Chemother* 1999; **43**: 1982–7.

47 Wright GE, Brown NC, Xu WC *et al*. Active site directed inhibitors of replication-specific bacterial DNA polymerases. *Bioorg Med Chem Lett* 2005; **15**: 729–32.

48 Daly JS, Giehl TJ, Brown NC *et al*. In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of gram-positive bacteria. *Antimicrob Agents Chemother* 2000; **44**: 2217–21.

49 Zhi C, Long ZY, Gambino J *et al*. Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase IIIC and Gram-positive bacterial growth. *J Med Chem* 2003; **46**: 2731–9.

50 Zhi C, Long ZY, Manikowski A *et al*. Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils. *J Med Chem* 2005; **48**: 7063–74.

51 Kuhl A, Svenstrup N, Ladel C *et al*. Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme. *Antimicrob Agents Chemother* 2005; **49**: 987–95.

52 Svenstrup N, Ehlert K, Ladel C *et al*. New DNA polymerase IIIC inhibitors: 3-subtituted anilinouracils with potent antibacterial activity in vitro and in vivo. *Chem Med Chem* 2008; **3**: 1604–15.

53 Butler MM, Skow DJ, Stephenson RO *et al*. Low frequencies of resistance among *Staphylococcus* and *Enterococcus* species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil. *Antimicrob Agents Chemother* 2002; **46**: 3770–5.

54 Barnes MH, Hammond RA, Kennedy CC *et al*. Localization of the exonuclease and polymerase domains of *Bacillus subtilis* DNA polymerase III. *Gene* 1992; **111**: 43–9.

55 Butler MM, Dudycz LW, Khan NN *et al*. Development of novel inhibitor probes of DNA polymerase III based on dGTP analogs of the HPUra type:

base, nucleoside and nucleotide derivatives of N2-(3,4-dichlorobenzyl)guanine. *Nucleic Acids Res* 1990; **18**: 7381–7.

56 Xu WC, Wright GE, Brown NC *et al*. 7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity. *Bioorg Med Chem Lett* 2011; **21**: 4197–202.

57 Rose Y, Ciblat S, Reddy R *et al*. Novel non-nucleobase inhibitors of *Staphylococcus aureus* DNA polymerase IIIC. *Bioorg Med Chem Lett* 2006; **16**: 891–6.

58 Guiles J, Sun X, Critchley IA *et al*. Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III. *Bioorg Med Chem Lett* 2009; **19**: 800–2.

59 Kelch BA. Review: the lord of the rings: structure and mechanism of the sliding clamp loader. *Biopolymers* 2016; **105**: 532–46.

60 Hedglin M, Kumar R, Benkovic SJ. Replication clamps and clamp loaders. *Cold Spring Harb Perspect Biol* 2013; **5**: a010165.

61 Kling A, Lukat P, Almeida DV *et al*. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. *Science* 2015; **348**: 1106–12.

62 Terlain B, Thomas JP. [Structure of griselimycin, polypeptide antibiotic extracted *Streptomyces* cultures. I. Identification of the products liberated by hydrolysis]. *Bull Soc Chim Fr* 1971; **6**: 2349–56.

63 Toyohara M. Aspects of the antituberculous activity of 27753-RP, a new semisynthetic derivative of griselimycine. *Ann Inst Pasteur Microbiol* 1987; **138**: 737–44.

64 Shereda RD, Kozlov AG, Lohman TM *et al*. SSB as an organizer/mobilizer of genome maintenance complexes. *Crit Rev Biochem Mol Biol* 2008; **43**: 289–318.

65 Marceau AH. Functions of single-strand DNA-binding proteins in DNA replication, recombination, and repair. *Methods Mol Biol* 2012; **922**: 1–21.

66 Marceau AH, Bernstein DA, Walsh BW *et al*. Protein interactions in genome maintenance as novel antibacterial targets. *PLoS One* 2013; **8**: e58765.

67 Lu D, Bernstein DA, Satyshur KA *et al*. Small-molecule tools for dissecting the roles of SSB/protein interactions in genome maintenance. *Proc Natl Acad Sci USA* 2010; **107**: 633–8.

68 Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. *J Antimicrob Chemother* 2003; **51**: 1109–17.

69 Spigaglia P, Barbanti F, Mastrantonio P *et al*. Fluoroquinolone resistance in *Clostridium difficile* isolates from a prospective study of *C. difficile* infections in Europe. *J Med Microbiol* 2008; **57**: 784–9.

70 Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol* 2008; **4**: 682–90.

71 Reddy MR. Advances in rational drug design. *Curr Pharm Des* 2013; **19**: 4673.

72 Pokrovskaya V, Baasov T. Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. *Expert Opin Drug Discov* 2010; **5**: 883–902.

73 Zhi C, Long ZY, Manikowski A *et al*. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. *J Med Chem* 2006; **49**: 1455–65.

74 Butler MM, Lamarr WA, Foster KA *et al*. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. *Antimicrob Agents Chemother* 2007; **51**: 119–27.

75 Butler MM, Shinabarger DL, Citron DM *et al*. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic *Clostridium difficile*. *Antimicrob Agents Chemother* 2012; **56**: 4786–92.

76 Phillips JW, Goetz MA, Smith SK *et al*. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in *Staphylococcus aureus*. *Chem Biol* 2011; **18**: 955–65.

77 Lu J, Patel S, Sharma N *et al*. Structures of kibdelomycin bound to *Staphylococcus aureus* GyrB and ParE showed a novel U-shaped binding mode. *ACS Chem Biol* 2014; **9**: 2023–31.

78 Miesel L, Hecht DW, Osmolski JR *et al*. Kibdelomycin is a potent and selective agent against toxigenic *Clostridium difficile*. *Antimicrob Agents Chemother* 2014; **58**: 2387–92.

79 Singh SB, Dayananth P, Balibar CJ *et al*. Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent. *Antimicrob Agents Chemother* 2015; **59**: 3474–81.

80 Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 2006; **124**: 837–48.

81 Vollaard EJ, Clasener HA. Colonization resistance. *Antimicrob Agents Chemother* 1994; **38**: 409–14.

82 Rea MC, Dobson A, O'Sullivan O *et al*. Effect of broad- and narrow-spectrum antimicrobials on *Clostridium difficile* and microbial diversity in a model of the distal colon. *Proc Natl Acad Sci USA* 2011; **108** Suppl 1: 4639–44.

83 Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. *Lancet Infect Dis* 2001; **1**: 101–14.

84 Pham TA, Lawley TD. Emerging insights on intestinal dysbiosis during bacterial infections. *Curr Opin Microbiol* 2014; **17**: 67–74.

85 Theriot CM, Koenigsknecht MJ, Carlson PE Jr *et al*. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to *Clostridium difficile* infection. *Nat Commun* 2014; **5**: 3114.

86 Chang JY, Antonopoulos DA, Kalra A *et al*. Decreased diversity of the fecal microbiome in recurrent *Clostridium difficile*-associated diarrhea. *J Infect Dis* 2008; **197**: 435–8.

87 Drekonja DM, Amundson WH, Decarolis DD *et al*. Antimicrobial use and risk for recurrent *Clostridium difficile* infection. *Am J Med* 2011; **124**: 1081.e1–7.

88 Smits WK, Lyras D, Lacy DB *et al*. *Clostridium difficile* infection. *Nat Rev Dis Primers* 2016; **2**: 16020.

89 Louie TJ, Miller MA, Mullane KM *et al*. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med* 2011; **364**: 422–31.

90 Tannock GW, Munro K, Taylor C *et al*. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of *Clostridium difficile*-infected patients than does vancomycin. *Microbiology* 2010; **156**: 3354–9.

91 Torti A, Lossani A, Savi L *et al*. *Clostridium difficile* DNA polymerase IIIC: basis for activity of antibacterial compounds. *Curr Enzym Inhib* 2011; **7**: 147–53.

92 Dvoskin S, Xu WC, Brown NC *et al*. A novel agent effective against *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2012; **56**: 1624–6.

93 Goldstein EJ, Citron DM, Tyrrell KL. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal *Clostridium* species: implications for *Clostridium difficile* recurrence. *Antimicrob Agents Chemother* 2014; **58**: 1187–91.

94 Weiss W, Pulse M, Vickers R. In vivo assessment of SMT19969 in a hamster model of *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2014; **58**: 5714–8.

95 Vickers R, Tinsley J, Storer R *et al*. SMT19969 – a novel antibiotic for *C. difficile*: *Clostridium difficile* growth inhibition, spectrum of activity and resistance development. Abstract B-1194. In: *Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA*, 2011. American Society for Microbiology, Washington, DC, USA.

96 Baraldi PG, Bovero A, Fruttarolo F *et al*. DNA minor groove binders as potential antitumor and antimicrobial agents. *Med Res Rev* 2004; **24**: 475–528.

97 Best E, Vickers R, Wilcox M, Effects of a novel antimicrobial (SMT19969) for treatment of *Clostridium difficile* infection (CDI) on gut flora. Abstract K-167. In: *Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA*, 2013. American Society for Microbiology, Washington, DC, USA.

98 Baines SD, Crowther GS, Freeman J *et al*. SMT19969 as a treatment for *Clostridium difficile* infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. *J Antimicrob Chemother* 2015; **70**: 182–9.

99 Steele J, Zhang Q, Beamer G *et al*. MBX-500 is effective for treatment of *Clostridium difficile* infection in gnotobiotic piglets. *Antimicrob Agents Chemother* 2013; **57**: 4039–41.

100 Gardiner L, Coyle BJ, Chan WC *et al*. Discovery of antagonist peptides against bacterial helicase-primase interaction in *B. stearothermophilus* by reverse yeast three-hybrid. *Chem Biol* 2005; **12**: 595–604.

101 McKay GA, Reddy R, Arhin F *et al*. Triaminotriazine DNA helicase inhibitors with antibacterial activity. *Bioorg Med Chem Lett* 2006; **16**: 1286–90.

102 Fossum S, De Pascale G, Weigel C *et al*. A robust screen for novel antibiotics: specific knockout of the initiator of bacterial DNA replication. *FEMS Microbiol Lett* 2008; **281**: 210–4.

103 Yamaichi Y, Duigou S, Shakhnovich EA *et al*. Targeting the replication initiator of the second *Vibrio* chromosome: towards generation of Vibrionaceae-specific antimicrobial agents. *PLoS Pathog* 2009; **5**: e1000663.

104 van Eijk E, Paschalis V, Green M *et al*. Primase is required for helicase activity and helicase alters the specificity of primase in the enteropathogen *Clostridium difficile*. *Open Biol* 2016; doi:10.1098/rsob.160272.